PECULIARITIES OF PSYCHOCORRECTION AND PSYCHOPROPHYLACTICS OF MAIN FORMS IN ANXIETY DISORDERS

Abstract

There were discussed results of psychocorrective and psychiprophilactic measures with consideration of typism and atypism of clinical manifestations as exemplified of 204 cases of generalized anxiety disorder (GAD) and 189 cases of panic disorder (PD).

Keywords

generalized anxiety disorder / panic disorder / psychocorrection / psychoprophylactics

References

[1] Менделевич В.Д. О некоторых психологических механизмах неврозогенеза // Психологический журнал. 1990. №6. С.113‒117

[2] Менделевич В.Д. Расстройства зависимого поведения (к постановке проблемы) // Российский психиатрический журнал. 2003. №1. С. 5‒9

[3] Старшенбаум А.В. Суицидология и кризисная психотерапия. М.: Когито-центр, 2005. 376 с

[4] Цыганков Д.Б., Малыгин В.Л., Агасарян Э.Г., Цыганков Б.Д. Психологические защиты у больных алкоголизмом и паническим расстройством // Журнал неврологии и психиатрии им. С.С. Корсакова. 2008. Т. 108, №11. С. 96–97

[5] Boden J.M., Fergusson D.M., Horwood L.J. Anxiety disorders and suicidal behaviors in adolescence and young adulthood: findings from a longitudinal study // Psychol. Med. 2007. Vol. 37. P. 431–440

[6] Davidson J.R., Wittchen H.U., Llorca P.M. et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo controlled trial // Eur. Neuropsychopharmacol. 2008. Vol. 18. P. 673–681

[7] Grant B.F., Hasin D.S., Stinson F.S. et al. Prevalence, correlates, comorbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the national epidemiologic survey on alcohol and related conditions // Psychol. Med. 2005. Vol. 35. P. 747–759

[8] Kessler R.C., Berglund P., Demler O. et al. Lifetime prevalence and age of onset distributions of DSM-IV disorders in the national comorbidity survey replication // Arch. Gen. Psychiatry. 2005. Vol. 62. P. 593–602

[9] Lorenz R.A., Jackson C.W., Saitz M. Adjunctive Use of Atypical Antipsychotics for Treatment-resistant Generalized Anxiety Disorder // Pharmacotherapy. 2010. Vol. 30(9). P. 942‒951

[10] Menza M.A., Dobkin R.D., Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder // J. Clin. Psychopharmacol. 2007. Vol. 27. P. 207–210

[11] Wittchen H.U. Generalized anxiety disorder: prevalence, burden, and cost to society // Depress Anxiety 2002. Vol. 16. P. 162–171

RIGHTS & PERMISSIONS

Yaltonsky V.M., Atamanov A.A.